Trial Profile

INTERNATIONAL MULTICENTER, OPEN-LABEL, PHASE 2 STUDY TO TREAT MOLECULAR RELAPSE OF PEDIATRIC ACUTE MYELOID LEUKEMIA WITH AZACITIDINE - AMoRe2017

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Acronyms AMoRe2017

Most Recent Events

18 Jan 2024 The trial has been discontinued in Netherlands (Global end date: 15 Dec 2023).
10 Jan 2024 The trial has been discontinued in Belgium, according to European Clinical Trials Database record.
21 Dec 2023 The trial has been completed in Germany (Global end date: 15 Dec 2013).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com